MicroPort CardioFlow Medtech Corporation (2160.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Ruinian Zhang
Listed since: Feb 4, 2021
Employees: 1,415

Market position

Day range

Current HK$1.325

HK$1.31HK$1.38

52-week range

Current HK$1.325

HK$0.93HK$7.95

Open: HK$1.38
Previous close: HK$1.38
Volume: 665.8K; 0.51× average
Average volume: 1.31M; Average daily volume
Market cap: 651.58M HKD
Beta: 0.32; Market reference 1
50-day average: HK$1.1904; +11.31% above average
200-day average: HK$3.2808; -59.61% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 4.24B HKD
P/E (TTM): -0.89×
P/B (TTM): 0.07×
P/S (TTM): 1.48×
EV / EBITDA: -38.03×
Earnings yield: -4.92%
Free cash flow yield: -10.00%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 54.65%
Operating margin: -27.20%
Net margin: -33.30%
Return on equity: -7.35%
Return on assets: -2.81%
Return on invested capital: -2.38%

Financial health

Debt / equity: 0.13×
Current ratio: 2.52×
Altman Z-score: -3.54
Piotroski F-score: 3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

443.79M HKD+796.19%

Operating income

−101.09M HKD-1078.71%

Net income

−146.41M HKD-2061.93%

Metric (HKD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	443.79M HKD	49.52M HKD	47.47M HKD	36.66M HKD	31.53M HKD
Cost of goods sold	155.46M HKD	15.11M HKD	15.01M HKD	12.88M HKD	12.89M HKD
Gross profit	288.34M HKD	34.41M HKD	32.46M HKD	23.68M HKD	18.64M HKD
Research and development	112.52M HKD	21.01M HKD	33.51M HKD	32.69M HKD	23.73M HKD
Selling, general, and administrative	295.31M HKD	30.47M HKD	41.4M HKD	34M HKD	24.76M HKD
Operating expenses	389.43M HKD	42.98M HKD	76.75M HKD	78.08M HKD	43.64M HKD
Interest income	7.9M HKD	10.4M HKD	12.22M HKD	5.64M HKD	3.88M HKD
Interest expense	1.71M HKD	517.02K HKD	552.77K HKD	757.74K HKD	3.08M HKD
Depreciation and amortization	41.59M HKD	3.36M HKD	10.39M HKD	2.62M HKD	914.68K HKD
Operating income	−101.09M HKD	−8.58M HKD	−44.29M HKD	−55M HKD	−25M HKD
Net income	−146.41M HKD	−6.77M HKD	−66.58M HKD	−66.37M HKD	−28.78M HKD